de Kruyk A R, van der Meulen J H, van Herwerden L A, Bekkers J A, Steyerberg E W, Dekker R, Habbema J D
Center for Clinical Decision Sciences, Department of Public Health, Erasmus University, Rotterdam, The Netherlands.
J Heart Valve Dis. 1998 Jan;7(1):4-12.
Several different biological, bioprosthetic and mechanical devices are available for heart valve replacement. We present a quantitative methodology to estimate the (event-free) life-expectancy and lifetime risk of valve-related events for individual patients after implantation of any one of these valve types.
We modelled the age-dependent prognosis of a patient after aortic valve replacement with a discrete-time Markov model and Monte-Carlo simulation to estimate (event-free) life-expectancy and life-time risk of valve-related events, respectively. Quantitative estimates to parameterize these models used hypothetical devices and presumed data were based on a limited review of published literature.
This decision-analytical approach allowed an estimation of the overall and event-free life-expectancy as well as the lifetime risk of valve-related events after implantation of different types of prosthetic heart valve in the aortic position. In the current, hypothetical model, one valve type excelled for all age groups in terms of life expectancy and life-time risk of valve-related events. The choice of the second-best alternative varied according to patient age and comorbidity. Sensitivity analyses showed results to be especially dependent on the durability of the replacement valve and surgical risk.
This methodological approach is very flexible, and its quantitative results may guide decision making, if increasing quantitative information on heart valve prosthesis performance becomes available in future. Markov models and Monte Carlo simulation may be used to obtain a better understanding of the effect that different types of prosthetic heart valves have on patient prognosis, while quantitative results may help cardiologists and cardiac surgeons to choose a specific valve type for an individual patient.
有几种不同的生物、生物假体和机械装置可用于心脏瓣膜置换。我们提出一种定量方法,以估计植入这些瓣膜类型中任何一种后个体患者的(无事件)预期寿命和瓣膜相关事件的终生风险。
我们用离散时间马尔可夫模型和蒙特卡洛模拟对主动脉瓣置换术后患者的年龄依赖性预后进行建模,分别估计(无事件)预期寿命和瓣膜相关事件的终生风险。用于参数化这些模型的定量估计使用了假设装置,且假定数据基于对已发表文献的有限综述。
这种决策分析方法能够估计在主动脉位置植入不同类型人工心脏瓣膜后的总体和无事件预期寿命以及瓣膜相关事件的终生风险。在当前的假设模型中,就预期寿命和瓣膜相关事件的终生风险而言,一种瓣膜类型在所有年龄组中表现最佳。次优选择因患者年龄和合并症而异。敏感性分析表明结果尤其取决于置换瓣膜的耐用性和手术风险。
这种方法非常灵活,如果未来能获得更多关于心脏瓣膜假体性能的定量信息,其定量结果可能会指导决策。马尔可夫模型和蒙特卡洛模拟可用于更好地理解不同类型人工心脏瓣膜对患者预后的影响,而定量结果可能有助于心脏病专家和心脏外科医生为个体患者选择特定的瓣膜类型。